Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Solid Biosciences up 10% Following J.P. Morgan Upgrade
Solid Biosciences Analyst Ratings
JPMorgan Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $15 From $10
Piper Sandler Reiterates Overweight on Solid Biosciences, Maintains $20 Price Target
Solid Biosciences Analyst Ratings
Komo: Maintaining the Solid Biosciences (SLDB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $12.00 to $10.00.
Solid Biosciences Analyst Ratings
JP Morgan Maintains Neutral on Solid Biosciences, Lowers Price Target to $10
Solid Biosciences Inc: J.P. Morgan cuts price target from $12 to $10
HC Wainwright & Co. : Solid Biosciences (SLDB.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $16.00.
Solid Biosciences Analyst Ratings
Buy Rating for Solid Biosciences Anchored on Robust Financials and Promising Clinical Prospects
Barclays: Maintaining the Solid Biosciences (SLDB.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $21.00 to $18.00.
Solid Biosciences Analyst Ratings
Solid Biosciences' SGT-003 Shows Promise: A Buy Rating With a High-Risk Upside
Barclays Remains a Buy on Solid Biosciences (SLDB)
Solid Biosciences Analyst Ratings
Solid Biosciences Analyst Ratings
Barclays Maintains Overweight on Solid Biosciences, Raises Price Target to $21